Target intelligence / Profile preview

K99 pilus antigen (K99) (K99)

Target
K99
Molecular classification
Bacterial surface protein, Adhesin, Fimbriae, Pilus
01

Overview

The K99 pilus antigen, also known as F5 fimbriae, is a filamentous surface protein found on certain strains of enterotoxigenic Escherichia coli (ETEC). It serves as a critical virulence factor by mediating the attachment of the bacteria to specific carbohydrate receptors, specifically N-glycolylneuraminic acid (Neu5Gc-GM3), on the intestinal epithelial cells of neonatal calves, lambs, and piglets [3, 7]. This adhesion is a prerequisite for colonization and the subsequent release of enterotoxins that cause severe, often fatal, diarrhea known as colibacillosis [2, 12]. Because of its essential role in pathogenesis, the K99 antigen is a primary target for veterinary vaccines and passive immunization strategies [9, 10]. Therapeutic interventions typically involve the administration of K99-specific monoclonal or polyclonal antibodies to neonates or the vaccination of pregnant dams to provide high levels of protective antibodies in the colostrum [6, 12]. By blocking the K99-mediated attachment, these treatments effectively prevent the establishment of infection in the gut [3, 6].

Other names
F5 fimbriaeF5 pilusK99 fimbrial adhesinFanC proteinF5 antigen
02

Mechanism of action

Neutralization of the K99 pilus antigen by specific antibodies prevents the attachment of enterotoxigenic Escherichia coli (ETEC) to the N-glycolylneuraminic acid (Neu5Gc) receptors on the intestinal brush border of neonatal animals. This blockade inhibits bacterial colonization and the subsequent production of enterotoxins, thereby preventing the development of severe diarrhea (colibacillosis).

03

Biological functions

Bacterial adhesionHost cell colonizationPathogenesis
04

Disease associations

Neonatal diarrheaColibacillosisEnterotoxigenic Escherichia coli infection
05

Safety considerations

Maternal antibody interference in neonatesSpecies-specific efficacy (primarily ruminants and swine)Potential for emergence of non-K99 fimbriated strainsLimited therapeutic window (neonatal period only)
06

Interacting drugs

Genecol 99

5 more in the full profile.

07

Biomarkers

K99 antigen detection in fecesK99-specific antibody titers in colostrumK99-specific antibody titers in serum

Beyond the preview

Go deeper on K99 pilus antigen (K99) (K99).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on K99 pilus antigen (K99) (K99).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call